

Form PTO-1449 Substitute U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Application Number	09/423,109
	Filing Date	October 29, 1999
	First Named Inventor	Jacques Paris, et al.
	Art Unit	1616
	Examiner Name	Sabiha Qazi
	Attorney Docket No.	6730/76555/JPW/LAD

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	1	4,820,831	04-11-1989	Ogata et al.
	2	5,108,995	04-28-1992	Casper
	3	5,256,421	10-26-1993	Casper
	4	5,585,370	12-17-1996	Casper
	5	5,382,573	01-17-1995	Casper
	6	4,826,831	05-02-1989	Plunkett
	7	5,208,225	05-04-1993	Boissonneault
	8	5,552,394	09-03-1996	Hodgen
	9	36,247	07-06-1999	Plunkett et al.
	10	2007/0281912 A1	12-06-2007	Jaques Paris

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
	11	EP 0 136 011 B1	01-22-1997	PLUNKETT ET AL	
	12	EP 0 309 263 A1	03-29-1989	JENCAP RESEARCH LTD	
	13	FR 2,737,411	02-07-1997	THERAMEX	
	14	FR 2,754,179	04-10-1998	THERAMEX	
	76	EP 0 235 090 A1	09-02-1987	BOISSENAULT	
	77	EP 0 235 607 A1	01-20-1998	UPTON ET AL.	
	78	EP 0 491 415 A1	06-24-1992	BERGINK	
	79	EP 1 227 814 B1	01-05-2005	THERAMEX	

EXAMINER
SIGNATURE

/Sabiha Qazi/

DATE CONSIDERED

12/20/2010

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Applicants: Jaques Paris, et al.

Serial No.: 09/423,109

Filed: October 29, 1999

Exhibit A

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.Q./

Form PTO-1449 Substitute		U.S. Department of Commerce Patent and Trademark Office		Application Number	09/423,109
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Filing Date	October 29, 1999
				First Named Inventor	Jacques Paris, et al.
				Art Unit	1616
				Examiner Name	Sabiha Qazi
				Attorney Docket No.	6730/76555/JPW/LAD
U.S. PATENT DOCUMENTS					
Examiner Initials¹	Cite No.¹	Document Number Number-Kind Code² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
FOREIGN PATENT DOCUMENTS					
Examiner Initials¹	Cite No.¹	Foreign Patent Document Country Code³ Number⁴ Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T⁶
	80	GB 2 216 420	10-11-1989	SANDOZ LTD	
	81	WO 96/09826	04-04-1996	SCHERING AG	
	82	WO 96/10991	04-18-1996	ASTRA AKTIEBOLAG	
	83	WO 97/04787	02-13-1997	THERAMEX	
	84	WO 98/15279	04-16-1998	THERAMEX	
	85	WO 01/30355 A1	05-03-2001	THERAMEX	
	86	WO 01/30358 A1	05-03-01	THERAMEX	
EXAMINER SIGNATURE /Sabiha Qazi/			DATE CONSIDERED 12/20/2010		

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Form PTO-1449 Substitute		U.S. Department of Commerce Patent and Trademark Office		Application Number	09/423,109
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Filing Date	October 29, 1999
				First Named Inventor	Jacques Paris, et al.
				Art Unit	1616
				Examiner Name	Sabiha Qazi
				Attorney Docket No.	6730/76555/JPW/LAD
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T²
	15	Affinito et al., (1998) "Ultrasonographic Measurement Of Endometrial Thickness During Hormonal Replacement Therapy In Postmenopausal Women" Ultrasound Obstet. Gynecol, 11:343-346			
	16	Basdevant et al., (1991) "Effects Of Nomegestrol Acetate (5 mg/D) On Hormonal, Metabolic And Hemostatic Parameters In Premenopausal Women" Contraception, 44(6):599-605			
	17	Bernard A. M. et al., (1994) "Menopausal: Bone and Therapeutic Regimens (Cont)." International Journal of Gynecology & Obstetrics, pp.124			
	18	Birkauser M. et al., (1995) "Substitution Hormonale: Une Indication Bien Posee et Des Schemas De Traitement Individuels Sont Déterminants Pour Le Succes Du Traitement" Med. et Hyg., 53:1770-3			
	19	Bocanera R et al., (1993). "Effect Of A HRT Regime (Micronized 17-Estradiol And Medroxy Progesterone Acetate) On The Endometria And Bleeding Pattern Of Climacteric Women" Bleeding and Endometrial Function, p.17, Abstract No. 40			
	20	Carranza-Lira, (1998). "Endometrial Changes According To Hormone Replacement Therapy Schedule" Menopause: The Journal of The North American Menopause Society, 5(2):86-89			
	21	Doren et al., (1996). "Long-Term Compliance Of Continuous Combined Estrogen And Progestogen Replacement In Postmenopausal Women." Journal of the Climacteric & Postmenopause, 25:99-105			
	22	Doren et al., "Uterine Perfusion And Endometrial Thickness In Postmenopausal Women On Long-Term Continuous Combined Estrogen And Progestogen Replacement" Ultrasound Obstet. Gynecol., 9:113-119			
	23	Doren & Scheider, (1996). "The Impacts Of Different HRT Regimens On Compliance" Int. J. Fertil., 41(1):29-39			
EXAMINER SIGNATURE		/Sabiha Qazi/		DATE CONSIDERED 12/20/2010	
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.</p>					

Form PTO-1449 Substitute		U.S. Department of Commerce Patent and Trademark Office		Application Number	09/423,109	
				Filing Date	October 29, 1999	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				First Named Inventor	Jacques Paris, et al.	
				Art Unit	1616	
				Examiner Name	Sabiha Qazi	
				Attorney Docket No.	6730/76555/JPW/LAD	
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T²
	24	Drapier Faure E. (1992). "Le Traitement De La Menopause Evitant Les Regles: Est-il Possible? Est-Il Souhaitable?" Gynecologie, 43(4-5):271-280, Including English Summary At P.271				
	25	Eiken et al.(1996)"Effects Of 10 Years' Hormone Replacement Therapy On Bone Mineral Content In Postmenopausal Women" Bone, 19(5):191S-193S				
	26	Eiken et al.(1997)."Effect On Bone Mass After Eight Years Of Hormonal Replacement Therapy" British Journal of Obstetrics And Gynecology 104:702-707				
	27	Eiken and Kolthoff, (1995)."Compliance With Long-Term Oral Hormonal Replacement Therapy" Maturitas 22:97-103				
	28	Ettinger et al.,(1998)."Comparison Of Continuation Of Postmenopausal Hormone Replacement Therapy: Transdermal Versus Oral Estrogen" Menopause: The Journal of the North American Menopause Society, 5(3):152-156				
	29	Fox H. et al, (1993)"Six Months Endometrial Histology Data On Continuous Estradiol Combined With 4 Different Dosages Of Continuous Dydrogesterone In More Than 300 Postmenopausal Women" Bleeding and Endometrial Function, p.40, Abstract 119				
	30	Hargrove J.T. et al.,(1998) "Menopausal Hormone Replacement Therapy With Continuous Daily Oral Micronized Estradiol And Progesterone", Obstetrics & Gynecology, 73:606-612				
	31	Hart et al., (1998) "Long-Term Effects Of Continuous Combined HRT On Bone Turnover And Lipid Metabolism In Postmenopausal Women" Osteoporosis Int., 1998, 8:326-332				
EXAMINER SIGNATURE		/Sabiha Qazi/		DATE CONSIDERED 12/20/2010		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.</p>						

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.Q./

Form PTO-1449 Substitute U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Application Number	09/423,109
	Filing Date	October 29, 1999
	First Named Inventor	Jacques Paris, et al.
	Art Unit	1616
	Examiner Name	Sabiha Qazi
	Attorney Docket No.	6730/76555/JPW/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	32	Kuhl (1996). "Comparative Pharmacology Of Newer Progestogens" Drugs, 51(2):188-215	
	33	Mizanuma et al., (1997). "Prevention Of Postmenopausal Bone Loss With Minimal Uterine Bleeding Using Low Dose Continuous Estrogen/Progestin Therapy: A 2 Year Prospective Study" Maturitas 27:69-76	
	34	Neumann, (1977). "Probleme der Dosisfindung:Sexualhormone" Drug. Res., pp. 296-318, Including English Summary At p.296	
	35	Oettel et al., (1999). "The Preclinical And Clinical Profile Of Dienogest: A Short Overview", Drugs of Today, 35:3-12	
	36	Paterson et al., (1980). "Endometrial Disease After Treatment With Oestrogens And Progestogens In The Climacteric" British Medical Journal, pp. 822-824	
	37	Piegsa et al., (1997). "Endometrial Status In Post-Menopausal Women On Long-Term Continuous Combined Hormone Replacement Therapy (Kliofem) A Comparative Study Of Endometrial Biopsy, Outpatient Hysteroscopy And Transvaginal Ultrasound" European Journal of Obstetrics & Gynecology, 72:175-180	
	38	Rauch and Taubert, (1993). "Continuous Hormone Replacement Therapy With Estradiol Valerate And Chlormadinone Acetate In Adjustable Dosages" Maturitas, 17:123-127	
	39	Recker et al., (1999). "The Effect Of Low-Dose Continuous Estrogen And Progesterone Therapy With Calcium And Vitamin D Bone In Elderly Women" Ann Internal Med., 130:897-904	
	40	Reubinoff et al., (1995). "Effects Of Hormone Replacement Therapy On Weight, Body, Composition, Fat Distribution, And Food Intake In Early Postmenopausal Women: A Prospective Study" Fertility and Sterility, 64(5):963-968	

EXAMINER SIGNATURE	/Sabiha Qazi/	DATE CONSIDERED	12/20/2010
---------------------------	---------------	------------------------	------------

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 Substitute		U.S. Department of Commerce Patent and Trademark Office		Application Number	09/423,109
				Filing Date	October 29, 1999
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				First Named Inventor	Jacques Paris, et al.
				Art Unit	1616
				Examiner Name	Sabiha Qazi
				Attorney Docket No.	6730/76555/JPW/LAD
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	41	Stadberg et al., (1996). "17B-Estradiol And Norethisterone Acetate In Low Doses As Continuous Combined Hormone Replacement Therapy" Maturitas, 23:31-39			
	42	Thomas et al., (1993). "Postmenopausal Hormone Therapy" 7th Intern. Cong. on the Menopause, Stockholm, Abstract No. 372			
	43	Ulrich et al., (1997). "Quality Of Life And Patient Preference For Sequential Versus Continuous Combined HRT: The UK Kliofem Multicenter Study Experience" International Journal of Gynecology & Obstetrics, 59:S11-S17			
	44	Whitehead et al., (1982). "Effects Of Various Types And Dosages Of Progestogens On The Postmenopausal Endometrium" The Journal of Reproductive Medicine, 27(8):539-548			
	46	Wolfe and Huff, (1995). "Effects Of Continuous Low-Dosage Hormonal Replacement Therapy On Lipoprotein Metabolism In Postmenopausal Women" Metabolism, 44(3):410-417			
	45	Wolfe and Plunkett, (1994). "Early Effects Of Continuous Low-Dosage D1-Norgestrel Administered Alone Or With Estrogen" Maturitas, 18:207-219			
	47	BERGINK, et al. (1981) "Effect Of Oestriol, Oestradiol Valerate And Ethinyloestradiol On Serum Proteins In Oestrogen-Deficient Women," Maturitas, 3 (3-4) : 241-247			
	48	BERNARD A. M. et al., (1994), Menopausal: Bone and Therapeutic Regimens (Cont). International Journal of Gynecology & Obstetrics, pp. 124			
	49	BOTELLA et al. "Regulation Of Rat Uterine Steroid Receptors By Nomegestrol Acetate, A New 19-Nor-Progesterone Derivative" Abstract of J. Pharmacol. Exp. Ther. 1989, Feb; 248(2): 758-61			
EXAMINER SIGNATURE		/Sabiha Qazi/		DATE CONSIDERED 12/20/2010	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.					

Form PTO-1449 Substitute		U.S. Department of Commerce Patent and Trademark Office		Application Number	09/423,109
				Filing Date	October 29, 1999
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				First Named Inventor	Jacques Paris, et al.
				Art Unit	1616
				Examiner Name	Sabiha Qazi
				Attorney Docket No.	6730/76555/JPW/LAD
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	50	BOTELLA et al. "Kinetic Analysis Of The Binding Of Nomegestrol Acetate To The Progesterone Receptors In Rat Uterus By Competition Studies" Fundam. Clin. Pharmacol. 1990; 4(5): 511-23			
	51	BOTELLA et al. "Lack Of Estrogenic Potential Of Progesterone- Or 17-Norprogesterone-Derived Progestins As Opposed To Testosterone Or 19-Nortestosterone Derivatives On Endometrial Ishikawa Cells" J. Steroid. Biochem. Mol. Biol. 1995, Oct; 55(1): 77-84			
	52	COHEN et al. "Traitement Des Femmes En Périménopause Par 5 Mg/J D'acétate De Nomégestrol, 20 Jours Par Cycle" Contracept. Fertl. Sex. (1992) - Vol. 20, n° 11, 1054-1057, including an English language abstract			
	53	CONRAD et al. "Cardiovascular Risk Factors and Combined Estrogen-Progestin Replacement Therapu: A Placebo-Controlled Study With Noegestrol Acetate and Estradiol", Fertility and Sterility, Vol. 64, No. 5, 1995, pp. 957-962			
	54	COUZINET et al. "The Antigonadotropic Activity Of Progestins (19-Norprogesterone And 19-Norprogesterone Derivatives) Is Not Mediated Through The Androgen Receptor" J. Clin. Endocrinol. Metab. 1996, Dec; 4218-4223			
	55	COUZINET B., et al. (1999) "The Antigonadotropic Activity Of A 19-Nor-Progesterone Derivative Is Exerted Both At The Hypothalamic And Pituitary Levels In Women," The Journal of Clinical Endocrinology & Metabolism, vol.84, n°11, pp.4191-4196			
	56	DESREUX et al. "Effects Of A Progestogen On Normal Human Breast Epithelial Apoptosis On Vitro And In Vivo" The Breast (2003), 12, 142-149			
	57	DORANGEON et al. "Effects Of Nomegestrol Acetate On Carbohydrate Metabolism" Diabete & Metabolisme (paris) (1993), 19, 441-445			
	58	DORANGEON et al. "Short Term Effects On Lipids And Lipoproteins Of Two Progestogens Used In Postmenopausal Replacement Therapy" European Journal of Clinical Research (1992), 3: 187-193			
EXAMINER SIGNATURE		/Sabiha Qazi/		DATE CONSIDERED 12/20/2010	

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.Q./

Form PTO-1449 Substitute		U.S. Department of Commerce Patent and Trademark Office		Application Number	09/423,109	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Filing Date	October 29, 1999	
				First Named Inventor	Jacques Paris, et al.	
				Art Unit	1616	
				Examiner Name	Sabiha Qazi	
				Attorney Docket No.	6730/76555/JPW/LAD	
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	59	DORANGEON et al. "Traitement De L'endométriopse Par L'acétate De Nomegestrol" Gynécologie, 1993, 1, 3, 139-143, including an English language abstract				
	61	DUC et al. "Interaction Of [3H] Nomegestrol Acetate With Cytosolic Progesterone Receptors From The Rat Uterus" Steroids, 1991, Jun; 56(6): 325-328				
	60	DUC at al. "Antiandrogenic Properties Of Nomegestrol Acetate" Arzneim. Forsch. Drug/Res. 1995, 45(1): 70-74				
	62	FOIDART et al. "Impact Of Percutaneous Oestradiol Gels In Postmenopausal Hormone Replacement Therapy On Clinical Symtoms And Endometrium" British Journal of Obstetrics and Gynaecology March (1997), Vol. 104, 305-310				
	63	LINDBERG et al. (1989) "A Comparison Between Effects Of Estradiol Valerate And Low Dose Ethinyl Estradiol On Haemostasis Parameters" Thrombosis & Haemostasis, 61(1), pp.65-9				
	64	NGUYEN -PASCAL et al. "Nomegestrol Acetate May Enhance The Skeletal Effects Of Estradiol On Biochemical Markers Of Bone Turnover In Menopausal Women After 12-Week Treatment Period" Climacteric 2005; 8: 136-145				
	65	PARIS, et al. (1983), "The Pharmacological Profile of TX 066 (17alpha-acetoxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione), a New Oral Progestative". Arzneimittelforschung, Vol. 33, No. 5, pp. 710-715				
	66	PARIS, et al. (1987) "Extinction Of Mineralocorticoid Effects In 19-Norprogesterone Derivatives: Structure-Activity Relationships," The Journal of Pharmacology and Experimental Therapeutics, vol.243, n°1, pp.288-291				
	67	POWERS et al., "Pharmacokinetics and Pharmacodynamics Of Transdermal Dosage Forms of 17beta-estradiol: Comparison With Conventional Oral Estrogens Used For Hormone Replacement", Am. J. Obstet. Gynecol. (1985), Vol. 152, No. 8, pp.1099-1106				
EXAMINER SIGNATURE		/Sabiha Qazi/		DATE CONSIDERED		12/20/2010
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.						

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.Q./

Form PTO-1449 Substitute U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Application Number	09/423,109
	Filing Date	October 29, 1999
	First Named Inventor	Jacques Paris, et al.
	Art Unit	1616
	Examiner Name	Sabiha Qazi
	Attorney Docket No.	6730/76555/JPW/LAD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	68	REYONLDS, J. "MARTINDALE, The Extra Pharmacopoeia - Sex Hormone" 30 th Edition Pharmaceutical Press (1993), pp. 1166-1198	
	69	Suplemento afna No. 1, Mayo 1991, Seccion II 57	
	70	THOMAS J. L., et al. "Les Progestatifs - Effets Biologiques Et Implications Thérapeutiques" Revue française d'Endocrinologie, Nutrition et Métabolisme, (1986), 27, n° 4-5, 389-403, including an English translation	
	71	TIMMER et al. "Bioequivalence Assessment Of Three Different Estradiol Formulations In Postmenopausal Women In An Open, Randomized, Single-Dose, 3-Way Cross-Over Study" Europ.J.Drug.Metab.& Pharmacol., 1999, vol.24, n°1, pp.47-53	
	72	VON SCHOULTZ, et al. (1989) "Estrogen Therapy And Liver Function-Metabolic Effects Of Oral And Parenteral Administration," Prostate, 14 (4), pp.389-395	
	73	WILLIAMS et al., (Nov. 1998) "Coadministration Of Noregestrol Acetate Does Not Diminish The Beneficial Effects Of Estradiol On Coronary Artery Dilator Responses In Nonhuman Primates (Macaca fascicularis)" Am. J. Obstet. Gynecol. Vol 179(5), pp.1288-1294	
	74	ZARTARIAN et al. (1998) "Effets Sur La Qualités Des Cycles Et Les Bouffées De Chaleur Du Nomégestrol Acétate Administré Seul Ou Associé En Séquentiel Inversé Au 17 Bêta Estradiol Cutané Chez Des Femmes En Périménopause" Contracept. Fertil. Sex. Vol 26 (1), pp. 69-76, including an English language abstract	
	75	ZARTARIAN et al. (1998) "Tolérance Biologique Et Clinique Du Nomégestrol Acétate, Administré Seul Puis Associé En Séquentiel Inversé Au 17 Bêta Estradiol Cutané, Chez Des Femmes À Risques Présentant Une Dyslipoprotéïnémie De Type IIa" Annales d'endocrinologie (Paris), 59, 411-416, including an English language abstract	
	87	BARRET-CONNOR et al., (1989) "Estrogen Replacement and Coronary Heart Disease" Cardiovascular clin., vol. 19, n°3, pp. 159-172	

EXAMINER SIGNATURE	/Sabiha Qazi/	DATE CONSIDERED	12/20/2010
---------------------------	---------------	------------------------	------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

[illegible]

/Sabiha Qazi/

12/20/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.Q./